Fate Therapeutics Inc (NASDAQ:FATE)
| 4.87 Delayed Data As of Jun 09 |  -0.435 / -8.21%Today’s Change | 4.02 Today|||52-Week Range 37.13 | -51.78% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $516.5M |
Company Description
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
Contact Information
Fate Therapeutics, Inc. 12278 Scripps Summit Drive San Diego California 92131 |
Employees
Shareholders
| Other institutional | 58.84% |
| Mutual fund holders | 51.90% |
| Individual stakeholders | 21.53% |
Top Executives
| J. Scott Wolchko | President, Chief Executive Officer & Director |
| Edward J. Dulac | Chief Financial Officer & Accounting Officer |
| Bahram Valamehr | Chief Research & Development Officer |
| Wen Bo Wang | Senior Vice President-Technical Operations |
| Yu Waye Chu | Chief Medical Officer |
